Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary

May 12, 2022

NASDAQ US Health Care Pharmaceuticals earnings 24 min

Earnings Call Speaker Segments

Jennifer Good

executive
#1

Good afternoon, everyone, and thank you for joining us for the business update and earnings call covering our first quarter of 2022. With me on today's call are Lisa Delfini, who serves as Trevi's Chief Financial Officer, and Dr. Bill Forbes, our Chief Development Officer. Lisa and I will begin with some prepared remarks, and after that, the 3 of us will be here to take your questions. On the clinical side, 2022 has already proven to be an exciting year for Trevi, and additional data is still ahead. During this call, we will share an update regarding the ongoing progress we are making as we advance development of both of our programs; but prior to that, I'd like to briefly discuss the pipeline strategy here at Trevi. Our focus is on the most debilitating elements of disease, where we also see a possible chance to become disease-modifying over time. Take pruritus and PN, for instance. The thinking goes like this: if a patient's itch can be reduced or suppressed, and the scratching urge goes down along with it, that breaks the itch-scratch cycle, giving the skin and nodules a chance to recover. So far, our clinical work has turned up evidence backing that idea. Now think about cough in IPF — some patients cough 1,500 times a day or more. If you can bring that cough down by a large margin, you may be able to reduce the mechanical trauma repeated coughing inflicts on the lungs, and that could mean wider gains for people living with IPF. So in each of the two programs we're running, we're looking at whether bringing relief to the areas of disease management that matter most could end up changing the disease process itself. That approach is what Trevi was built around, and it's genuinely thrilling that key data from both of our indications will be read out over the next few months. Let me walk you through where each program stands right now. The one furthest along in the clinic targets severe chronic pruritus in prurigo nodularis, or PN — a condition that is serious and debilitating, marked by papules and nodules appearing on the skin together with continuous, intense itching. Our PRISM study, a Phase IIb/III trial running 14 weeks, is evaluating Haduvio for PN. Given how refractory this condition is, we think PN has a neurological basis, which could mean it pairs nicely with the neural action of our mixed agonist-antagonist compound. The majority of these individuals have already gone through topical options without success, and we expect that going forward, patients will qualify for an oral option such as Haduvio prior to moving on to biologics. Several key milestones for this trial have been hit during the year. We randomized our final participant at the close of January, and word has just come in that this last patient finished the final visit within the double-blind phase of the trial. We remain on schedule to deliver data before June finishes. Our clinical group is scrubbing the information and getting ready for database lock; we're eager to review what comes out. Shifting to our second clinical effort, which targets chronic cough tied to idiopathic pulmonary fibrosis, also known as IPF. During Q1, we were very happy to share positive results from a prespecified interim efficacy analysis, which allowed us to halt enrollment earlier than anticipated, reduce expenses, and accelerate into the next phase of development. Based on that interim look, by day 22 Haduvio yielded a 77% drop from baseline in daytime cough frequency, as captured by an objective cough monitor, amounting to a 52% gap relative to placebo. Just think about what a 77% drop in coughing could mean for someone who coughs as many as 1,500 times each day. For this interim analysis involving 26 subjects, the p-value came in at P less than 0.0001, and conditional power reached 100%. Such findings held steady no matter the baseline cough frequency or whether antifibrotics were used. Patient reported outcomes, or PROs, back up the striking findings from the objective cough monitor. The PRO item measuring cough frequency shows separation from placebo-treated subjects beginning at day 1 and did better among subjects taking Haduvio than those on placebo at every time point. Haduvio is the leading therapy being developed for cough in IPF and stands alone as the only one to demonstrate favorable outcomes for reducing cough among this patient population. Haduvio was well tolerated throughout this study, with just one SAE that was not considered treatment related, and the adverse events matched what we have observed in Haduvio trials across other indications. 26 subjects took part in the interim analysis, and we anticipate roughly 40 subjects overall will be assessed in the final data. Given how strong the reported p-value is, we would anticipate comparable findings in the final data set and look forward to announcing data covering the full set of subjects during Q3 of this year. Bill and his group have been putting in a lot of effort to prepare for the upcoming IPF cough trial. To date, they've put together a draft of a protocol synopsis, which we intend to set up as a trial that is adequate and well-controlled, and they've also asked for a meeting with the FDA so we can review the design together; that FDA meeting should happen during the third quarter of this year. These interim results are exciting and provide some early support for what we've theorized about the way Haduvio's mechanism acts when it comes to treating cough. And collectively, we're figuring out how to move ahead, not only for this indication but for other chronic cough indications as well. It's estimated that the global chronic cough market is valued at roughly $10 billion. Things have gotten off to a hectic start in 2025 at Trevi, but there's still a great deal left to accomplish. The coming months will bring us a wealth of data, and after that we'll move into the next phase of development. We're eager to get PRISM results in June, along with complete CANAL data across every subject during Q3. Based on our knowledge of how Haduvio works and the compelling cough findings we've gathered, we're in a solid position to expand Trevi. Now I'll turn it over to Lisa for a review of the financials, and once she's done, we'll open the floor to your questions. Lisa?

Lisa Delfini

executive
#2

Thanks, Jennifer, and good afternoon to all of you. Just a reminder that the complete financial results covering the 3 months that ended March 31, 2022 are available in our press release that went out before this call, as well as in our 10-Q, filed with the SEC today once the market closed. I want to start by discussing events that occurred after the quarter ended; on April 11, we brought in $55 million by selling common stock and prefunded warrants to new investors along with any long-time investor who decided to take part as well. Pricing for the offering was at market, with no warrant coverage attached. Frazier, Venrock, and Fairmount are the new investors, and all three are well-known biotech investors, and we're thrilled to have their support as we move our programs forward. We also brought in proceeds of $4.5 million in April tied to warrants being exercised that had originally been issued in our October 2021 private placement. Combined with our cash balance of $29 million as of the end of March, I'm happy to say we now hold over $80 million in cash and investments. Our ongoing operations will be funded by these proceeds, which includes finishing our current PRISM trial along with its open-label extension, plus planning and running our next trial for chronic cough in IPF. This provides us with cash runway into Q1 of 2024; beyond that, roughly 15 million warrants remain outstanding, which could bring in up to $20 million, should they be exercised; moving now to first quarter results. During the first quarter of 2022, our net loss came to $7.3 million, versus a net loss of $8.4 million in the same quarter of 2021. R&D expenses totaled $4.6 million in the first quarter of 2022, versus $5.6 million during the same period of 2021, largely driven by lower clinical trial subject recruitment cost as our PN trial finishes enrollment this year. Consulting expenses and professional fees also decreased because we used fewer consulting services and because the professional recruiting fees tied to hiring in the prior year period did not recur. G&A expenses came to $2.4 million in the first quarter of 2022, versus $2.5 million during the same period of 2021, mostly because legal fees were lower due to the timing of certain intellectual property filings. To wrap up, we are excited about the company's strategy, the data we recently reported in IPF cough, and the strength of our balance sheet as we keep executing on our plan. That brings our prepared remarks to a close. I'll now hand the call back to the operator for Q&A.

Serge Belanger

analyst
#3

Let me kick things off with a pair of questions about the PN program, and in particular the PRISM trial. Once we receive a readout at the close of June, is a top line all we should anticipate? Or are we also going to get the secondary endpoints, plus the complete safety results? Then for my second one, perhaps you could bring us up to date on how the open-label extension part of that study is progressing?

Jennifer Good

executive
#4

Bill, would you like to handle that?. Sure, please go ahead.

Bill Forbes

executive
#5

Yeah. Serge, thanks for those questions. I'll take this one. Regarding what you should anticipate on the top line, I believe, in terms of giving you guidance, we'll share whatever data we have on hand. So my expectation is a top line plus a few secondary endpoints and a safety summary too; my hope is that we can deliver all of it when we report in June. The open-label portion is ongoing. Some patients are still completing it. So we're continuing to gather data from that as well. That will likely carry us through roughly the coming 6 months.

Serge Belanger

analyst
#6

Alright. So if that comes back positive, a second Phase III trial in PN would be required. Could you give us a rough estimate of what that Phase III trial might cost? And perhaps the time lines too? I realize those are hard to pin down. But since the second trial should happen in a better COVID environment than the first one did, maybe just give us a sense of how the time lines might improve.

Bill Forbes

executive
#7

Sure. I'll likely hand the budget question over to Lisa, but yes, we've been telling people that a second study in this indication is probably needed. So my hope is that we can complete the whole rollout of it within the next couple of years. Clearly, how large that study ends up being will matter a great deal. Still, we're confident because more than 60 centers took part in PRISM; we'll bring in additional patients — or additional centers, rather. And naturally, with luck, the second study won't require as many patients either; so with a lot of hypotheticals in play, hopefully it takes roughly 2 years in the in-clinic phase for it to wrap up. Lisa, I'm not sure whether you'd like to take the study cost question.

Lisa Delfini

executive
#8

Yeah, regarding what the study will cost, I mean, we've still got to run a proper RFP and everything like that. So there isn't a precise figure yet, though our estimate puts it somewhere between $20 million and $30 million.

Annabel Samimy

analyst
#9

I'm just considering how big another chronic cough study in IPF would be. What shape do you think that would take, and what scale? The reason I ask is that you might be able to run 2 sizable late-stage programs at the same time. Do you believe you're in a spot where you'd have to rank them according to what each program is worth; so how do you view conducting 2 programs at once? And do you have any idea how big that upcoming chronic cough trial will be?

Bill Forbes

executive
#10

Sure. I'll kick things off, and perhaps, Jennifer, you may want to jump in on a few of these. But here's what we're examining, and we've said this quite openly. At present, we figure we'll enroll roughly 300 patients in the upcoming study, 100 patients in each treatment arm; we expect that enrollment will take 18 to 24 months, and we're going to make every effort to hold it to 12 months, if we can; however, if enrollment stretches to 18 months, then follow-up would be 6 months. So it would be a couple of years once more. But clearly, the efficacy measure there would simply be cough count. So let me provide a bit more detail on this, Annabel. But we'll be looking at cough counts. But one point I've stated quite openly is that we don't require many patients to demonstrate efficacy, and we know from our Phase II experience that extremely few patients are needed to produce a statistical difference. We're keen to track these patients for 6 months. That way we can begin to determine whether or not we're affecting their disease itself. We expect that once we relieve them of this type of cough, the quantity of cough these patients experience, they will fare very well from a respiratory standpoint, and I believe that will factor into hospitalizations and respiratory distress they endure and a reduction in respiratory exacerbations. So I think, by and large, we'll track them for now. We forecast we'll track them for 6 months. And we need to reach the FDA. And as Jennifer said during her remarks, we'll talk with them in Q3. So I'm not sure, Jennifer, whether I left anything out.

Jennifer Good

executive
#11

No. On the staffing question you raised, Annabel, I'd simply say this: my sense is we're in good shape. A solid development group is already with us, and under Bill we have a robust clin-ops function, so running these two studies at the same time is within our reach. A few additional people or positions might come in. What makes me more uneasy — and this likely factors into certain choices we make, plus other indications as they gradually fade into entirely unfamiliar territory. This drug, as you're aware, we believe holds wide usefulness. Still, provided we remain within pruritus and cough, I'm at ease regarding our capacity to conduct 2 trials concurrently.

Annabel Samimy

analyst
#12

All right. And if I may just ask a quick follow-up touching on both subjects, actually. So regarding your talk about evaluating for possible disease modification — I think with PN, measuring healing is fairly straightforward; so in the case of chronic cough, when you consider disease modification, will you be looking at measures such as FVC? Or what exactly will you use to gauge disease modification for chronic cough?

Bill Forbes

executive
#13

Yes. Well, I'd say the antifibrotics have managed a fairly solid job of attempting to bring some of this to light. I think we will examine changes in FVC, even though 6 months is somewhat brief for observing anything of that kind. But I suspect we will likely zero in on measures such as hospitalization, particularly respiratory hospitalizations stemming from respiratory illness. And I think there are a few additional items we would like to examine more closely. So we're discussing those, and I don't want to get ahead of myself on certain aspects of this, so we want to hold a discussion with the FDA about it; but I think when it comes to exacerbation of IPF, if you simply take a look and consider what the antifibrotics have accomplished in attempting to measure improvement in some of these areas, we will count several of those same sorts of things. And we'll have an open-label study that will permit us to follow these patients for a longer period, as well; so the 6 months on placebo will provide us an event rate within our population. The open-label study that we conduct will let these patients flow into it, and we can track them for an even longer time. So I think we'll determine over time whether or not cutting cough, in roughly half of these patients by as much as 75% reduction in their daytime cough, we'll find out if that converts into better respiratory function over time.

Annabel Samimy

analyst
#14

All right, understood. Then, if I could squeeze in one final item regarding where you source from. You brought up warrants, sure, yet could there be additional avenues for turning the ex-U.S. chance into revenue, giving you extra boost so these current programs reach their fullest potential?

Jennifer Good

executive
#15

Indeed; during the past 12 months we've stayed occupied with that, getting ready for the results to come out. Clearly, we won't attempt to sell this across Europe or in any nation in Asia. Thus, we've held ongoing talks with numerous collaborators; they await the data. I believe choices regarding our approach need to be made. Still, revenue can be generated from it. Plus, as you noted, I think that means adding certain development know-how within those regions. In the U.S. and Europe, I'm at ease; our experience runs deep, and Bill has navigated every one of those markets securing clearances, yet I do believe tapping into their insights on pricing along with certain other matters proves useful. Hence, after all these data readouts finish, we'll aim to pursue that.

Nathan Weinstein

analyst
#16

Jennifer and Lisa, 2 things from me. First, about how Haduvio might modify the disease itself — could you offer some big-picture perspective on what such a profile would mean for this drug's commercial opportunity, compared with a scenario where people see it only as something that eases symptoms?

Jennifer Good

executive
#17

Sure, I'll take that one. Clearly, if it turns out to have a disease-modifying effect, I believe Annabel mentioned certain FVCs that run longer. That said, the antifibrotics carry an annual price tag of roughly $140,000 per year. If instead you're only addressing the serious cough dimension of the condition — which I still consider pretty significant — then it won't fall into that disease modification bucket. Because of that, our thinking on pruritus pricing has consistently placed it near biologics, with a discount of some kind applied. Biologics sit at approximately 40,000; so I'd likely suggest a range running from that pricing point all the way up toward the disease-modifying end. Ultimately the data will decide it. So there's a wide range and plenty of variation there, yet everything hinges on what Bill can read out from this trial.

Nathan Weinstein

analyst
#18

Understood, got it. Then only one more item on my end about the nearby uses. You all have stated quite openly that big potential markets exist beyond the primary indications. Perhaps you could discuss the way you view that built-in optionality. And from a strategic standpoint, which routes could you pursue to access it?

Jennifer Good

executive
#19

Right. So we will be certain to read out the results from both of those trials and get both programs underway, provided the data backs it. Obviously, cough does; for PN, we will hold off. Therefore, our top priority will involve advancing the uses to which we have already made a commitment. Past that, a great deal of internal effort is underway to get ready for additional markets, pricing-type planning, and I believe regarding the resourcing question, what capacity we possess; so we will probably battle through one or possibly 2 more indications down the line that might be reasonable, I think, to assist in genuinely expanding the company. Thus that work is happening, and my expectation is that after we have all the data and can navigate the route ahead, we can provide some direction on it.

Jennifer Good

executive
#20

Everyone, we appreciate you joining us on today's call. Our gratitude also goes out to the Trevi team, to the investigators involved in our studies, and to each person who has taken part in our clinical trials. Thank you.

Operator

operator
#21

That brings us to the end of this call. We appreciate your joining us for today's presentation. You're welcome to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.